Forge Biologics
3900 Gantz Rd
Grove City
OH
43123
United States
Website: https://www.forgebiologics.com/
Email: careers@forgebiologics.com
53 articles about Forge Biologics
-
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation
3/19/2024
Forge Biologics today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101.
-
Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote
1/29/2024
Forge Biologics (Forge), a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, announced a clinical update today on five patients with Krabbe disease that have received FBX-101, an AAV gene therapy, after hematopoietic stem cell transplantation (HSCT).
-
Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production
12/12/2023
Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production.
-
BioSpace spoke to analysts and players in the contract manufacturing and development organizations space to assess the challenges this year and what lies ahead in 2024.
-
The Japanese biotechnology and food company has bought into the gene therapy space with its $620 million acquisition of Ohio-based CDMO and clinical-stage biotech Forge Biologics.
-
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1
11/13/2023
Ajinomoto Co., Inc. and Forge Biologics, announced that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million.
-
Forge Biologics Selected as an AAV Manufacturing Partner for California Institute for Regenerative Medicine to Help Accelerate Gene Therapy Programs
10/11/2023
Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to help advance the manufacturing of adeno-associated adenovirus (AAV) gene therapy programs from the state of California.
-
Forge Biologics to Participate in Multiple September Investor Conferences
9/5/2023
Forge Biologics, a leading manufacturer of genetic medicines, announced today that company leadership will be delivering presentations, participating in fireside chats, and taking one-on-one meetings at four September investor conferences.
-
New Hope Research Foundation and Forge Biologics Announce cGMP Manufacturing Partnership to Accelerate Gene Therapy for Patients with Tay-Sachs Disease
6/28/2023
The New Hope Research Foundation and Forge Biologics announced today a development and cGMP manufacturing partnership to advance the Foundation’s novel gene therapy, NHR01, into Phase I/II clinical trials for patients with GM2 gangliosidosis,
-
Forge Biologics Joins Bespoke Gene Therapy Consortium (BGTC) as Partner to Accelerate the Development and Manufacturing of AAV Gene Therapies for Patients with Rare Diseases
5/23/2023
Forge Biologics, a leading manufacturer of genetic medicines, announced today that it has joined the Bespoke Gene Therapy Consortium (BGTC), a public-private collaboration to accelerate the delivery of promising new gene therapies to patients with rare diseases.
-
Forge Biologics Announces Eight Presentations at the Upcoming 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)
5/11/2023
Forge Biologics will be delivered during the upcoming 26th Annual Meeting of the American Society of Gene and Cell Therapy.
-
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases
5/8/2023
Life Biosciences and Forge Biologics today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.
-
Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration
5/3/2023
Forge Biologics, a leading manufacturer of genetic medicines, today announced a gene therapy development and manufacturing collaboration with Labcorp (NYSE: LH), a leading global life sciences company.
-
Forge Biologics Receives Qualified Person (QP) Declaration to Manufacture AAV Gene Therapies to Support European Clinical Programs
4/24/2023
Forge Biologics announced that its manufacturing facility has successfully completed the audits necessary and received QP declaration for its gene therapy manufacturing facility, thereby fulfilling the European Union Good Manufacturing Practices requirement to manufacture investigational medicinal products and allowing Forge to support European-based clinical trials.
-
Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium
2/23/2023
Forge Biologics announced today that Maria Escolar, M.D., Chief Medical Officer, will present updated data from the RESKUE Phase 1/2 clinical trial for FBX-101 during the 19th Annual WORLD Symposium being held February 22-26, 2023, in Orlando, Florida.
-
Forge Biologics Deepens Genetic Medicine CDMO Capabilities with Leadership Team Expansion Across cGMP Manufacturing, Analytical Development, and Client Development
1/25/2023
Forge Biologics today the addition of three key leadership hires to further the Company’s growth as a leading manufacturer of genetic medicines.
-
Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease
1/17/2023
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that the European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge’s lead adeno-associated virus (AAV) drug candidate and novel gene therapy for treating patients with Krabbe disease.
-
Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership
1/10/2023
Oculogenex and Forge Biologics today announced a manufacturing partnership to help support the advancement of Oculogenex’s gene therapy program for dry age-related macular degeneration (AMD) toward clinical trials.
-
Forge Biologics, a Leading Manufacturer of Genetic Medicines, to Present at 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Forge Biologics, a Leading Manufacturer of Genetic Medicines, to Present at 41st Annual J.P. Morgan Healthcare Conference.
-
Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership
11/29/2022
Eikonoklastes Therapeutics and Forge Biologics today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).